{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:45:31Z","timestamp":1767833131936,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40801-023-00375-1","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:01:41Z","timestamp":1686207701000},"page":"383-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Liver Injury Following Isoniazid Preventive Therapy in HIV Patients Attending Halibet National Referral Hospital, Eritrea: A Prospective Cohort Study"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-5842","authenticated-orcid":false,"given":"Mulugeta","family":"Russom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-0883","authenticated-orcid":false,"given":"Daniel Y. B.","family":"Jeannetot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0815-2917","authenticated-orcid":false,"given":"Araia","family":"Berhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-0024","authenticated-orcid":false,"given":"Henok G.","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-9762","authenticated-orcid":false,"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-4904","authenticated-orcid":false,"given":"Katia M. C.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"375_CR1","volume-title":"Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO; 2011."},{"issue":"6","key":"375_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bcp.12885","volume":"81","author":"I Metushi","year":"2016","unstructured":"Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016;81(6):1030\u20136. https:\/\/doi.org\/10.1111\/bcp.12885.","journal-title":"Br J Clin Pharmacol"},{"key":"375_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/tx500285k","volume":"28","author":"X Meng","year":"2015","unstructured":"Meng X, Maggs JL, Usui T, et\u00a0al. Auto-oxidation of isoniazid leads to isonicotinic-lysine adducts on human serum albumin. Chem Res Toxicol. 2015;28:51\u20138. https:\/\/doi.org\/10.1021\/tx500285k.","journal-title":"Chem Res Toxicol"},{"key":"375_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/hep.26564","volume":"59","author":"IG Metushi","year":"2014","unstructured":"Metushi IG, Sanders C, Acute Liver Study G, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology. 2014;59:1084\u201393. https:\/\/doi.org\/10.1002\/hep.26564.","journal-title":"Hepatology"},{"key":"375_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","volume":"3","author":"V Ramappa","year":"2013","unstructured":"Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3:37\u201349. https:\/\/doi.org\/10.1016\/j.jceh.2012.12.001.","journal-title":"J Clin Exp Hepatol"},{"key":"375_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.freeradbiomed.2013.07.038","volume":"65","author":"KK Lee","year":"2013","unstructured":"Lee KK, Fujimoto K, Zhang C, et\u00a0al. Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes. Free Radic Biol Med. 2013;65:584\u201394. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.07.038.","journal-title":"Free Radic Biol Med"},{"key":"375_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/clpt.2010.355","volume":"89","author":"IG Metushi","year":"2011","unstructured":"Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011;89:911\u20134. https:\/\/doi.org\/10.1038\/clpt.2010.355.","journal-title":"Clin Pharmacol Ther"},{"key":"375_CR8","unstructured":"World Health Organization. Adverse events associated with the use of isoniazid preventive therapy among people living with HIV. WHO information note; 2015, Geneva, Switzerland."},{"issue":"1","key":"375_CR9","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2352-3018(20)30299-X","volume":"8","author":"JM Ross","year":"2021","unstructured":"Ross JM, Badje A, Rangaka MX, et\u00a0al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV. 2021;8(1):e8\u201315. https:\/\/doi.org\/10.1016\/S2352-3018(20)30299-X.","journal-title":"Lancet HIV."},{"issue":"2","key":"375_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5501\/wjv.v4.i2.105","volume":"4","author":"C Akolo","year":"2015","unstructured":"Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, et\u00a0al. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodefciency virus-infected persons. World J Virol. 2015;4(2):105\u201312. https:\/\/doi.org\/10.5501\/wjv.v4.i2.105.","journal-title":"World J Virol."},{"issue":"Suppl5","key":"375_CR11","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1097\/01.aids.0000391019.10661.66","volume":"24","author":"AD Grant","year":"2010","unstructured":"Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS. 2010;24(Suppl5):S29-36. https:\/\/doi.org\/10.1097\/01.aids.0000391019.10661.66.","journal-title":"AIDS"},{"issue":"5","key":"375_CR12","doi-asserted-by":"publisher","first-page":"13761384","DOI":"10.1378\/chest.14-0215","volume":"147","author":"Z Tedla","year":"2015","unstructured":"Tedla Z, Nguyen ML, Sibanda T, Nyirenda S, Agizew TB, Girde S, et\u00a0al. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest. 2015;147(5):13761384.","journal-title":"Chest"},{"issue":"9944","key":"375_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","volume":"384","author":"MX Rangaka","year":"2014","unstructured":"Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et\u00a0al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind placebo-controlled trial. Lancet. 2014;384(9944):682\u201390.","journal-title":"Lancet"},{"issue":"1","key":"375_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5588\/ijtld.11.0820","volume":"17","author":"SM Le Roux","year":"2013","unstructured":"Le Roux SM, Cotton MF, Myer L, le Roux DM, Schaaf HS, Lombard CJ, et\u00a0al. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. Int J Tuberc Lung Dis. 2013;17(1):26\u201331. https:\/\/doi.org\/10.5588\/ijtld.11.0820.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"375_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/QAI.0000000000001641","volume":"78","author":"M Ngongondo","year":"2018","unstructured":"Ngongondo M, Miyahara S, Hughes MD, et\u00a0al. Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with hiv with severe immunosuppression: a secondary analysis of a multi-country open-label randomized controlled clinical trial. J Acquir Immune Defic Syndr. 2018;78(1):54\u201361. https:\/\/doi.org\/10.1097\/QAI.0000000000001641.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"375_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40801-019-0147-3","volume":"6","author":"T Mudzviti","year":"2019","unstructured":"Mudzviti T, Shamu T, Chimbetete C, Munengerwa T, Bote S, Pascoe M. Tolerability of isoniazid preventive therapy in an hiv-infected cohort of paediatric and adolescent patients on antiretroviral therapy from a resource-limited setting: a retrospective cohort study. Drugs Real World Outcomes. 2019;6:37\u201342. https:\/\/doi.org\/10.1007\/s40801-019-0147-3.","journal-title":"Drugs Real World Outcomes."},{"issue":"2","key":"375_CR17","first-page":"2167","volume":"8","author":"M Russom","year":"2019","unstructured":"Russom M, Berhane A, Debesai M, Andom H, Tesfai D, Zeremariam Z, et\u00a0al. Challenges of hepatotoxicity associated with isoniazid preventive therapy among people living with HIV in Eritrea. Adv Pharmacoepidemiol Drug Saf. 2019;8(2):2167.","journal-title":"Adv Pharmacoepidemiol Drug Saf."},{"issue":"12","key":"375_CR18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/tmi.12609","volume":"20","author":"J van Griensven","year":"2015","unstructured":"van Griensven J, Choun K, Chim B, Thai S, Lorent N, Lynen L. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. Trop Med Int Health. 2015;20(12):1823\u201331.","journal-title":"Trop Med Int Health"},{"key":"375_CR19","doi-asserted-by":"publisher","first-page":"e00423","DOI":"10.1002\/prp2.423","volume":"6","author":"M Russom","year":"2018","unstructured":"Russom M, Debesai M, Zeregabr M, Berhane A, Tekeste T, Teklesenbet T. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. Pharmacol Res Perspect. 2018;6:e00423.","journal-title":"Pharmacol Res Perspect"},{"key":"375_CR20","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2147\/RMHP.S368315","volume":"15","author":"M Russom","year":"2022","unstructured":"Russom M, Jeannetot DYB, Tesfamariam S, Stricker BH, Verhamme K. Perspectives of healthcare professionals on factors limiting implementation of isoniazid preventive therapy in people living with HIV in Eritrea: a qualitative study. Risk Manag Healthc Policy. 2022;15:1407\u201319. https:\/\/doi.org\/10.2147\/RMHP.S368315.","journal-title":"Risk Manag Healthc Policy."},{"key":"375_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et\u00a0al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"375_CR22","unstructured":"Internet. https:\/\/www.cdc.gov\/epiinfo\/index.html. Accessed Mar 2021."},{"issue":"9","key":"375_CR23","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","volume":"27","author":"Z Shubber","year":"2013","unstructured":"Shubber Z, Calmy A, Andrieux-Meyer I, et\u00a0al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27(9):1403\u201312. https:\/\/doi.org\/10.1097\/QAD.0b013e32835f1db0.","journal-title":"AIDS"},{"key":"375_CR24","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2020. https:\/\/www.Rproject.org\/. Accessed Feb 2022."},{"issue":"11","key":"375_CR25","first-page":"1374","volume":"14","author":"H Kunst","year":"2010","unstructured":"Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010;14(11):1374\u201381.","journal-title":"Int J Tuberc Lung Dis"},{"key":"375_CR26","doi-asserted-by":"publisher","unstructured":"Sotgiu G, Matteelli A, Getahun H, et\u00a0al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. European Respiratory Journal. 2015 45: 1170-1173. https:\/\/doi.org\/10.1183\/09031936.00216814. URL: http:\/\/ow.ly\/HyjAH.","DOI":"10.1183\/09031936.00216814"},{"key":"375_CR27","unstructured":"Antibiotice S. A. Summary of product characteristics of isoniazid 300 mg tablet (TB266). Updated June 2014. (Accessed on 25 Jul 2022)"},{"key":"375_CR28","unstructured":"Micro Labs Limited. Summary of product characteristics of isoniazid 300 mg tablet (TB174). WHOPAR part 4. Updated February 2019."},{"key":"375_CR29","unstructured":"Internet. Medicines Sans Frontiers. Medical Guidelines: Tuberculosis. URL: https:\/\/medicalguidelines.msf.org\/viewport\/TUB\/latest\/chapter-16-treatment-of-latent-tuberculosis-infection-20322864.html (accessed 19 Apr 2022)"},{"key":"375_CR30","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention\u2013tuberculosis preventive treatment. Geneva: 2020.","DOI":"10.30978\/TB2021-2-86"},{"key":"375_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30678","volume":"141","author":"W Wang","year":"2017","unstructured":"Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141:1018\u201328.","journal-title":"Int J Cancer"},{"key":"375_CR32","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2018;41:760\u20135.","journal-title":"Am J Clin Oncol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00375-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:13:34Z","timestamp":1694193214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00375-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00375-1","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"30 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research work was self-funded by the lead author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All information gathered is included in the manuscript and additional information can be obtained from the corresponding author via: satiswt@gmail.com or m.russomghebremedhin@erasmusmc.nl.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethical approval to conduct the study was obtained from the Health Research Ethics and Protocol Review Committee of the Ministry of Health of the State of Eritrea (<i>reference number: 7-18\/2020<\/i>). Written consent was obtained from the study participants and all ethical and professional considerations were followed to ensure patient confidentiality. Thus, only anonymized information is reported. The study was performed in accordance with the ethical standards as laid down in the latest version (2013) of the 1964 Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Considerations"}},{"value":"Prior to enrollment, written consent was obtained from each study participant to take part in the study and their anonymised data to be reported in an international arena.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"Not required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not required.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The idea was conceived by MR, KV and BHS. All authors made a significant contribution in the design and follow-up of the study and interpretation of the results. Data was analysed by HGW. Data collection, supervision and data analysis processes were led by MR. The manuscript was drafted by MR and critically reviewed and edited by the rest of the authors. Finally, all the authors gave approval of the manuscript to be published in the journal and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}